life scienc tool diagnost
ep exce consensu elan ep
beat estim lighter revenu disproport off-set
stronger profit rais ep
reflect latest ep upsid pt move higher
view greater convict longer term profit prospect
revenu light profit shine revenu decreas
estim flat price volum impact fx
elanco excl strateg exits/fx increas plan ca diseas
prev ex-fx well view competit pressur
vaccin last gen parasiticid despit addit credelio dose
ca climb well plan work
gallipr backord launch europ livestock futur protein
expand strength poultri aqua flat growth
ruminant/swin sale estimate asf asia
though better fear gross margin rose meaning bp
bp plan sg fell bp continu cost structur
initi ebitda margin rose bp nice ahead plan
bp plan flow balanc sheet disclosur absent
pre-cal viewshar rebound elan share declin
recent high april vs share rise
despit mix cc top-line growth view impress
beat profit indic solid execut cost structur initi
expect call commentari parasiticid weak quarterli
progress core growth trend driver cost structur upsid
visibl thereon pipelin updat asf impact trade
ebitda discount view justifi
inher execut risk across less diversifi portfolio risk
epidemiolog competit cost structur execut fx dynam
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
fourth largest anim health pharmaceut compani
focus develop therapeut supplement
livestock companion anim diversifi portfolio includ
brand market countri
price may rate neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario assum greater expect
adopt product launch expedit pipelin success
meaning profit ramp on-going oper effici
initi specif increment million
annual sale product launch increment bp
oper profit margin expans would drive upsid
current ep estim support blue sky scenario
grey sky scenario assum draconian
fundament backdrop companion product anim health
fundament greater competit headwind new exist
product line lower expect ramp profit
separ parent specif flat top-line growth
bp ramp profit would translat ep
growth contribut grey sky scenario
 close
detail elan perform rel estim consensu
expect figur figur highlight forecast elan core organ top-line
revenu segment
food anim futur protein
food anim rumin swine
food anim futur protein
food anim rumin swine
impact
janssen
driven
contribut
partial off-set pressur
competit companion
anim bravecto nexgard
pressur food anim
vfd gener ractopamin
note growth rate base financi report compani commentari includ result posilac agristat retained/divest
otherwis includ elanco histor result futur project posilac agristat contribut million combin revenu repres anim
revenu growth rate includ janssen acquisit close chemgen acquisit close late januari growth includ roughli one month
impact chemgen acquisit growth adjust lohmann acquisit close april estim lohmann contribut result base
eli lilli commentari lohmann contribut growth growth lohmann contribut disclos estim averag contribut
arriv contribut lohmann growth includ lohmann impact includ novarti revenu base year eli lilli disclos
novartiss contribut growth exclud contribut bivi vaccin portfolio
compani mention price
